The nuclear receptor superfamily of steroid hormones and vitamin D gene regulation: An update

Annals of the New York Academy of Sciences

Volumn 1192, Issue , 2010, Pages 208-214

  Margolis, Ronald N ^a   Christakos, Sylvia ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Nuclear receptor; Steroid hormones; Vitamin D

Indexed keywords

CALCITRIOL; CELL NUCLEUS RECEPTOR; STEROID HORMONE; VITAMIN D;

BREAST CANCER; CHROMATIN; CONFERENCE PAPER; DRUG MECHANISM; EPIGENETICS; GENE ACTIVITY; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE LOCATION; GENE TARGETING; GENETIC TRANSCRIPTION; GENOME; HORMONE RESPONSE; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOPRECIPITATION; NONHUMAN; OSTEOLYSIS; PROTEIN ANALYSIS; PROTEIN TARGETING;

EID: 77950631691     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05227.x     Document Type: Conference Paper

References (40)

1. Mangelsdorf, D.J., C. Thummel, M. Beato, et al. 1995. The nuclear receptor superfamily: the second decade. Cell 83: 835-839.
2. Keay, J. & J.W. Thornton. 2009. Hormone-activated estrogen receptors in annelid invertebrates: implications for evolution and endocrine disruption. Endocrinology 150: 1731-1738.
3. Evans, R.M. 2005. The nuclear receptor superfamily: a rosetta stone for physiology. Mol. Endocrinol. 19: 1429-1438.
4. Moore, D.D., S. Kato, W. Xie, et al. 2006. International union of pharmacology. LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor, farnesoid X receptor, liver X receptor, liver X receptor, and vitamin D receptor. Pharmacol. Rev. 58: 742-759.
5. Bensinger, S.J., & P. Tontonoz, 2008. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454: 470-477.
6. Benoit, G., A. Cooney, V. Giguere, et al. 2006. International union of pharmacology. LVXI. Orphan nuclear receptors. Pharmacol. Rev. 58: 798-836.
7. Li, L., X. Xie, J. Qin, et al. 2009. The nuclear orphan receptor COUP-TFII plays an essential role in adipogenesis, glucose homeostasis, and energy metabolism. Cell Metab. 9: 77-87.
8. Bookout,A.L., Y. Jeong,M.Downes, et al. 2006.Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126: 789-799.
9. Yang, X., K.A. Lamia & R.M. Evans. 2007. Nuclear receptors, metabolism, and the circadian clock. Cold Spring Harbor Symp. Quant. Biol. 72: 387-394.
10. Bonnelye, E. & J.E. Aubin. 2005. REVIEW: estrogen receptor-related receptor alpha: a mediator of estrogen response in bone. J. Biol. Chem. 280: 3104-3111.
11. Kim, H-J., H. Zhao, H. Kitaura, et al. 2006. Glucocorticoids suppress bone formation via the osteoclast. J. Clin. Invest. 116: 2152-2160.
12. Pike, J.W., M.B. Meyer, M. Watanuki, et al. 2007. Perspectives on mechanisms of gene regulation by 1, 25-dihydroxyvitamin D3 and its receptors. J. Steroid Biochem. Mol. Biol. 103: 389-395.
13. Wan, Y., L.W. Chong & R.M. Evans. 2007. PPAR-gamma regulates osteoclastogenesis in mice. Nat.Med. 13: 1486-1503.
14. Grey, A., M. Bolland, G. Gamble, et al. 2007. The peroxisome- proliferator-activated receptor-gammaagonist rosiglitagazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J. Clin. Endocrinol. Metab. 92: 1305-1310.
15. Kininis, M. & W.L. Kraus. 2008. A global view of transcriptional regulation by nuclear receptors: gene expression, factor localization, and DNA sequence analysis. Nuclear Receptor Signaling 6. doi:10, 1621/nrs.06005.
16. Rosenfeld, M.G., V.V. Lunyak & C.K. Glass. 2006. Sensors and signals: a coactivator/corepressors/epigenetic code for integrating signaling-dependent programs of transcriptional response. Genes Dev. 20: 1405-1428.
17. Lonard, D.M., R. Lanz & B.W. O'Malley. 2007. Nuclear receptor coregulators and human disease. Endocr. Rev. 28: 575-587.
18. Jung, S.Y., A.Malovannaya, J.Wei, et al. 2005. Proteomic analysis of steady-state nuclear hormone receptor coactivator complexes. Mol. Endocrinol. 2451-2465.
19. Chopra, A.R., J.F. Louet, P. Saha, et al. 2008. Absence of the SRC-2 coactivator results in a glycogenopathy resembling Von Gierke's disease. Science 322: 1395-1399.
20. Chandra, V., P. Huang, Y. Hamuro, et al. 2008. Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA. Nature 456: 350-356.
21. Carroll, J.S. & M. Brown. 2006. Estrogen receptor target gene: an evolving concept. Mol. Endocrinol. 8: 1707-1714.
22. Euskirschen, G.M., J.S. Rozowsky, C.-L.Wei, et al. 2007. Mapping of transcription factor binding regions in mammalian cells by ChIP: comparison of array- and sequencing-based technologies. Genome Res. 17: 898-909.
23. N.J. McKenna, A.J. Cooney, F.J. DeMayo, et al. 2009. Evolution of NURSA, the nuclear receptor signaling atlas. Mol. Endocrinol. 23: 740-746.
24. Lanz,R.B.,Z. Jericevic,W.J.Zuercher, et al. 2006.Nuclear receptor signaling atlas (www.nursa.org): hyperlinking the nuclear receptor signaling community. Nucl. Acids Res. 34: D221-D226.
25. Christakos S. 2008. VitaminDGene Regulation. In Principles of Bone Biology, 3rd ed. J. Bilezikian, L. Raisz & T. Martin, Eds.: 779-794. Elsevier. San Diego, CA.
26. Christakos, S., P. Dhawan, Q. Shen, et al. 2006. New insights into themechanisms involved in the pleiotropic actions of 1,25dihydroxyvitamin D3. Ann. N.Y. Acad. Sci. 1068: 194-203.
27. Christakos, S. & Y. Zhong. 2007.Novelmechanism of vitamin D receptor activation: histoneH3 lysine 9 methyltransferase is a transcriptional coactivator for VDR. J. Bone Miner. Res. 22: S8.
28. Amling,M.,M.Priemel,T.Holzmann, et al. 1999.Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology 140: 4982-4987.
29. Dupret, J.M., P. Brun, C. Perret, et al. 1987. Transcriptional and post-transcriptional regulation of vitamin D-dependent calcium-binding protein gene expression in the rat duodenum by 1,25-dihydroxycholecalciferol. J. Biol. Chem. 262: 16553-16557.
30. Benn, B.S., D. Ajibade, A. Porta, et al. 2008. Active intestinal calcium transport in the absence of transient receptor potential vanilloid type 6 and calbindin-D9k. Endocrinology 149: 3196-3205.
31. Van Cromphaut, S.J., M. Dewerchin, J.G. Hoenderop, et al. 2001. Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. Proc. Natl. Acad. Sci. USA 98: 13324-13329.
32. Meyer, M.B., M. Watanuki, S. Kim, et al. 2006. The human transient receptor potential vanilloid type 6 distal promoter contains multiple vitamin D receptor binding sites that mediate activation by 1,25-dihydroxyvitamin D3 in intestinal cells. Mol. Endocrinol. 20: 1447-1461.
33. Bianco, S.D., J.B. Peng, H. Takanaga, et al. 2007.Marked disturbance of calcium homeostasis in mice with targeted disruption of the Trpv6 calcium channel gene. J. Bone Miner. Res. 22: 274-285.
34. Fujita,H., K. Sugimot, S. Inatomi, et al. 2008. Tight junction proteins claudin-2 and -12 are critical for vitamin Ddependent Ca2+ absorption between enterocytes. Mol. Biol. Cell 19: 1912-1921.
35. Kim, S., M. Yamazaki, L.A. Zella, et al. 2006. Activation of receptor activator of NF-kappaB ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long-range enhancers. Mol. Cell Biol. 26: 6469-6486.
36. Dhawan, P., R. Wieder & S. Christakos. 2009. CCAAT enhancer-binding protein alpha is a molecular target of 1,25-dihydroxyvitamin D3 in MCF-7 breast cancer cells. J. Biol. Chem. 284: 3086-3095.
37. Joshi, S., S. Youssef, L. Gaffen, et al. 2008. A key mechanism underlying the immunosuppressive effects of vitamin D: 1,25dihydroxyvitamn D3 is a transcriptional modulator of IL-17. J. Bone Miner. Res. 23: S105.
38. Liu, P.T., S. Stenger, H. Li, et al. 2006. Toll-like receptor triggering of a vitamin D-mediated humanantimicrobial response. Science 311: 1770-1773.
39. Yim, S., P. Dhawan, C. Ragunath, et al. 2007. Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25-dihydroxyvitamin D(3). J. Cyst. Fibros. 6: 403-410.
40. Gombart, A.F., N. Borregaard & H.P. Koeffler. 2005.Human cathelicidin antimicrobial peptide (CAMP) is a direct target of the vitamin D receptor and is strongly regulated inmyeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 19: 1067-1077.